The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

z5.keio.jp Objectives To investigate the possible role of baseline plasma tumour necrosis factor alpha levels (baseline-TNF) on the clinical response to infliximab in patients with rheumatoid ...

The mechanism of resistance to anti-tumour necrosis factor α (anti-TNFα ... synthase 2 (PTGS2), interleukin 13 receptor alpha 2 (IL13Ralpha2) and interleukin 11 (IL11), and predicted the response to ...

Recently biological blockade with the tumour necrosis factor alpha (TNFα) antagonists infliximab and etanercept has been shown to be effective in the treatment of SpA. However, only infliximab is ...

including tumour necrosis factor-alpha (TNF-α) inhibition with infliximab, adalimumab or certolizumab pegol, and chemokine receptor CCR9 inhibition with CCX282-B.14 Safety is an important concern when ...

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...

A study by Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with ...

Tumor necrosis factor alpha (TNF α) is involved in cell differentiation, mitogenesis, cytotoxic responses, inflammation, immunomodulation, and wound healing. Because of its numerous roles ...

TNF-α is a potent inducer of the inflammatory response, a key regulator of innate immunity and plays an important role in the regulation of Th1 immune responses against intracellular bacteria and ...